XML 25 R10.htm IDEA: XBRL DOCUMENT v3.25.2
REVENUE
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard and Oncotype® tests. The services are considered completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended June 30,Six Months Ended June 30,
(In thousands)2025202420252024
Screening
Medicare Parts B & C$226,888 $195,337 $428,570 $369,127 
Commercial339,465 283,729 623,698 537,872 
Other62,128 52,540 116,220 99,405 
Total Screening628,481 531,606 1,168,488 1,006,404 
Precision Oncology
Medicare Parts B & C$47,601 $47,467 $93,808 $95,517 
Commercial48,033 49,187 96,303 95,887 
International55,256 46,722 106,843 91,255 
Other31,714 24,282 52,428 47,725 
Total Precision Oncology182,604 167,658 349,382 330,384 
Total$811,085 $699,264 $1,517,870 $1,336,788 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics, LLC tests while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. Adjustments to revenue recognized during the period relating to prior period estimates were less than 1% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and six months ended June 30, 2025 and 2024.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not significant as of June 30, 2025 and December 31, 2024.
Revenue recognized for the three and six months ended June 30, 2025 and 2024 that was included in the deferred revenue balance at the beginning of the period was not significant.